Cisapride is a medication used to treat heartburn associated with GERD. In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.
- Mechanism
- Curator reviewed
Cisapride acts through the stimulation of the serotonin 5-HT4 receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
- Primary indication
- For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.Curator reviewed · 1 structured indication
- Formula / weight
- C23H29ClFN3O4 · 465.945 g/mol (avg)
- First approval
- Canada, 1990 · United States, 1993
- Code names
- R-51,619
Resolves to
DCSUBABJRXZOMT-IRLDBZIGSA-NSMILESCO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Cisapride, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account